PortalPublikationenRevisiting the predictors of a sustained virologic response ...

Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus

Standard

Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus. / Beinhardt, Sandra; Rutter, Karoline; Stättermayer, Albert Friedrich; Ferenci, Peter.

in: CLIN INFECT DIS, Jahrgang 56, Nr. 1, 01.01.2013, S. 118-22.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Beinhardt, S, Rutter, K, Stättermayer, AF & Ferenci, P 2013, 'Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus', CLIN INFECT DIS, Jg. 56, Nr. 1, S. 118-22. https://doi.org/10.1093/cid/cis843

APA

Beinhardt, S., Rutter, K., Stättermayer, A. F., & Ferenci, P. (2013). Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus. CLIN INFECT DIS, 56(1), 118-22. https://doi.org/10.1093/cid/cis843

Vancouver

Beinhardt S, Rutter K, Stättermayer AF, Ferenci P. Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus. CLIN INFECT DIS. 2013 Jan 1;56(1):118-22. https://doi.org/10.1093/cid/cis843

Bibtex

@article{ea573eaeab4d48e087d7a6b5ac9c5f61,
title = "Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus",
abstract = "Several host (age, sex, race, fibrosis stage, interleukin 28B polymorphism) and viral factors (hepatitis C virus [HCV] genotype, viral load) allow estimating the response to interferon-based therapies (which includes first-generation protease inhibitors) before treatment. However, treatment should not be denied to any patient based on unfavorable factors alone. Metabolic conditions associated with poor response (diabetes, insulin resistance, obesity) and alcohol abuse can be influenced before starting treatment. {"}On-treatment{"} predictors of response allow treatment to be tailored to the individual need of the patient. Patients with undetectable HCV RNA after 4 weeks (rapid virologic response [RVR]) have the highest chance for cure (>85%) both by dual and triple therapy. For triple therapy, the decision to shorten treatment requires that the virus remains undetectable for an additional 8 (telaprevir) to 20 (boceprevir) weeks (extended RVR). Based on viral kinetics, an even earlier prediction after 2 weeks of treatment with direct acting antivirals appears feasible.",
keywords = "Adult, Antiviral Agents, Female, Hepacivirus, Hepatitis C, Host-Pathogen Interactions, Humans, Interferon-alpha, Interleukins, Male, Polyethylene Glycols, RNA, Viral, Recombinant Proteins, Ribavirin, Sensitivity and Specificity, Treatment Outcome, Viral Load",
author = "Sandra Beinhardt and Karoline Rutter and St{\"a}ttermayer, {Albert Friedrich} and Peter Ferenci",
year = "2013",
month = jan,
day = "1",
doi = "10.1093/cid/cis843",
language = "English",
volume = "56",
pages = "118--22",
journal = "CLIN INFECT DIS",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus

AU - Beinhardt, Sandra

AU - Rutter, Karoline

AU - Stättermayer, Albert Friedrich

AU - Ferenci, Peter

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Several host (age, sex, race, fibrosis stage, interleukin 28B polymorphism) and viral factors (hepatitis C virus [HCV] genotype, viral load) allow estimating the response to interferon-based therapies (which includes first-generation protease inhibitors) before treatment. However, treatment should not be denied to any patient based on unfavorable factors alone. Metabolic conditions associated with poor response (diabetes, insulin resistance, obesity) and alcohol abuse can be influenced before starting treatment. "On-treatment" predictors of response allow treatment to be tailored to the individual need of the patient. Patients with undetectable HCV RNA after 4 weeks (rapid virologic response [RVR]) have the highest chance for cure (>85%) both by dual and triple therapy. For triple therapy, the decision to shorten treatment requires that the virus remains undetectable for an additional 8 (telaprevir) to 20 (boceprevir) weeks (extended RVR). Based on viral kinetics, an even earlier prediction after 2 weeks of treatment with direct acting antivirals appears feasible.

AB - Several host (age, sex, race, fibrosis stage, interleukin 28B polymorphism) and viral factors (hepatitis C virus [HCV] genotype, viral load) allow estimating the response to interferon-based therapies (which includes first-generation protease inhibitors) before treatment. However, treatment should not be denied to any patient based on unfavorable factors alone. Metabolic conditions associated with poor response (diabetes, insulin resistance, obesity) and alcohol abuse can be influenced before starting treatment. "On-treatment" predictors of response allow treatment to be tailored to the individual need of the patient. Patients with undetectable HCV RNA after 4 weeks (rapid virologic response [RVR]) have the highest chance for cure (>85%) both by dual and triple therapy. For triple therapy, the decision to shorten treatment requires that the virus remains undetectable for an additional 8 (telaprevir) to 20 (boceprevir) weeks (extended RVR). Based on viral kinetics, an even earlier prediction after 2 weeks of treatment with direct acting antivirals appears feasible.

KW - Adult

KW - Antiviral Agents

KW - Female

KW - Hepacivirus

KW - Hepatitis C

KW - Host-Pathogen Interactions

KW - Humans

KW - Interferon-alpha

KW - Interleukins

KW - Male

KW - Polyethylene Glycols

KW - RNA, Viral

KW - Recombinant Proteins

KW - Ribavirin

KW - Sensitivity and Specificity

KW - Treatment Outcome

KW - Viral Load

U2 - 10.1093/cid/cis843

DO - 10.1093/cid/cis843

M3 - SCORING: Journal article

C2 - 23024292

VL - 56

SP - 118

EP - 122

JO - CLIN INFECT DIS

JF - CLIN INFECT DIS

SN - 1058-4838

IS - 1

ER -